Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026)
Avalo Therapeutics (AVTX) posted Cash & Equivalents of $147000.0 for Q1 2026, down 99.07% on a QoQ basis from $15.9 million in Q4 2025, and up 137.1% year-over-year from $62000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $147000.0 for Q1 2026.
- Quarterly Cash & Equivalents rose 137.1% year-over-year to $147000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147000.0 (up 137.1% YoY) and the FY2025 annual result came in at $15.9 million, down 88.21% from the prior year.
- Cash & Equivalents was $147000.0 for Q1 2026 at Avalo Therapeutics, down from $15.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $134.5 million in Q4 2024 and bottomed at $4000.0 in Q1 2024.
- A 5-year average of $19.5 million and a median of $3.2 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 49333.33% — and 2024, when it slumped 99.98%.
- Avalo Therapeutics' Cash & Equivalents stood at $15000.0 in 2022, then jumped by 49333.33% to $7.4 million in 2023, then surged by 1714.51% to $134.5 million in 2024, then slumped by 88.21% to $15.9 million in 2025, then plunged by 99.07% to $147000.0 in 2026.
- Business Quant data shows AVTX's Cash & Equivalents at $147000.0 in Q1 2026, $15.9 million in Q4 2025, and $90000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 15.86 Mn |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 134.55 Mn |
| Sep 30, 2024 | 81.86 Mn |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 7.42 Mn |
| Sep 30, 2023 | 10.18 Mn |
| Jun 30, 2023 | 6.31 Mn |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 164,000.00 |
| Jun 30, 2021 | 40.44 Mn |
| Mar 31, 2021 | 38.29 Mn |